JP2021532059A5 - - Google Patents

Info

Publication number
JP2021532059A5
JP2021532059A5 JP2020554461A JP2020554461A JP2021532059A5 JP 2021532059 A5 JP2021532059 A5 JP 2021532059A5 JP 2020554461 A JP2020554461 A JP 2020554461A JP 2020554461 A JP2020554461 A JP 2020554461A JP 2021532059 A5 JP2021532059 A5 JP 2021532059A5
Authority
JP
Japan
Prior art keywords
alkyl
halo
pharmaceutical composition
cycloalkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020554461A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021532059A (ja
JP7532259B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/026112 external-priority patent/WO2019195761A2/en
Publication of JP2021532059A publication Critical patent/JP2021532059A/ja
Publication of JP2021532059A5 publication Critical patent/JP2021532059A5/ja
Application granted granted Critical
Publication of JP7532259B2 publication Critical patent/JP7532259B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020554461A 2018-04-05 2019-04-05 眼疾患治療薬剤 Active JP7532259B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862653249P 2018-04-05 2018-04-05
US62/653,249 2018-04-05
US201862694729P 2018-07-06 2018-07-06
US62/694,729 2018-07-06
PCT/US2019/026112 WO2019195761A2 (en) 2018-04-05 2019-04-05 Pharmacological agents for treating ocular diseases

Publications (3)

Publication Number Publication Date
JP2021532059A JP2021532059A (ja) 2021-11-25
JP2021532059A5 true JP2021532059A5 (https=) 2022-04-13
JP7532259B2 JP7532259B2 (ja) 2024-08-13

Family

ID=68101528

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020554461A Active JP7532259B2 (ja) 2018-04-05 2019-04-05 眼疾患治療薬剤

Country Status (6)

Country Link
US (1) US11872236B2 (https=)
JP (1) JP7532259B2 (https=)
CN (1) CN112601513B (https=)
BR (1) BR112020020351A2 (https=)
MX (1) MX2020010502A (https=)
WO (1) WO2019195761A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120097859A (zh) * 2019-02-19 2025-06-06 加利福尼亚大学董事会 Nurr1受体调节剂
CA3141998A1 (en) * 2019-05-31 2020-12-03 Plex Pharmaceuticals, Inc. Pharmacological agents for treating protein aggregation diseases of the eye
WO2021086834A1 (en) * 2019-10-28 2021-05-06 Kebotix, Inc. Electronic control of transmittance of visible and near-infrared radiation
WO2022098847A1 (en) * 2020-11-04 2022-05-12 Corino Therapeutics, Inc. Tolcapone analogs and methods of use
EP4243798A4 (en) * 2020-11-13 2024-08-21 Plex Pharmaceuticals, Inc. PHARMACOLOGICAL AGENTS FOR TREATING OCULAR PATHOLOGIES
CN116963727A (zh) * 2020-11-13 2023-10-27 普莱克斯医药公司 用于治疗眼部病症的药剂
US20250019352A1 (en) * 2021-06-29 2025-01-16 Plex Pharmaceuticals, Inc. Pharmacological agents for treating ophthalmic diseases
GB202204798D0 (en) 2022-04-01 2022-05-18 Bial Portela & Ca Sa Prodrugs of opicapone
WO2024123100A1 (ko) * 2022-12-09 2024-06-13 경희대학교 산학협력단 신규 아밀로이드-베타 응집체 분해제와 이를 이용한 뇌 표적화 약물 전달 시스템

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK175069B1 (da) * 1986-03-11 2004-05-24 Hoffmann La Roche Pyrocatecholderivater
US5236952A (en) * 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
JPH1036257A (ja) * 1996-05-22 1998-02-10 Kikkoman Corp メイラード反応阻害剤
ID19540A (id) 1997-01-22 1998-07-23 Hoffmann La Roche Metode pembuatan turunan-turunan benzofenon
JP2000256259A (ja) * 1999-03-11 2000-09-19 Nippon Zoki Pharmaceut Co Ltd メイラード反応阻害剤
US8299079B2 (en) * 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
WO2011047412A1 (en) * 2009-10-22 2011-04-28 The Heart Research Institute Ltd Tyrosine and l-dopa for reducing l-dopa incorporation into proteins
EP2566333A4 (en) * 2010-05-07 2014-04-02 Univ Leland Stanford Junior IDENTIFICATION OF STABILIZERS OF MULTIMEDER PROTEINS
WO2014147464A2 (en) 2013-03-20 2014-09-25 Ra Chem Pharma Limited Novel process for the preparation of tolcapone
US20160317474A1 (en) 2013-12-18 2016-11-03 Emory University Managing Visual Dysfunction or Loss of Vision for Diabetic Subjects
CA2938466C (en) 2014-02-08 2021-11-02 Genentech, Inc. Methods of treating alzheimer's disease
SG11201701377YA (en) * 2014-08-22 2017-03-30 Kang Zhang Compositions and methods to treat vision disorders
US10555922B2 (en) 2015-09-04 2020-02-11 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
EP4243798A4 (en) 2020-11-13 2024-08-21 Plex Pharmaceuticals, Inc. PHARMACOLOGICAL AGENTS FOR TREATING OCULAR PATHOLOGIES
CN116963727A (zh) 2020-11-13 2023-10-27 普莱克斯医药公司 用于治疗眼部病症的药剂

Similar Documents

Publication Publication Date Title
JP2021532059A5 (https=)
JP2023523130A5 (https=)
JP2024520481A5 (https=)
JP2023535453A5 (https=)
JP2023164918A5 (https=)
JP2010508296A5 (https=)
JP2015206991A5 (https=)
RU2009125232A (ru) Арильные соединения в качестве лигандов ppar и их применение
JP2019501130A5 (https=)
JP2018531218A5 (https=)
JP2020535124A5 (https=)
JP2013137517A5 (https=)
EA201171214A1 (ru) Асфальто-минеральные композиции
JP2020063289A5 (https=)
JP2014134773A5 (https=)
JP2025507292A5 (https=)
JP2022533958A5 (https=)
JP2017197539A5 (https=)
JP2021513543A5 (https=)
JP2025502943A5 (https=)
JP2019500376A5 (https=)
JP2018535261A5 (https=)
JP2021532158A5 (https=)
JP2021532183A5 (https=)
JP2022509763A5 (https=)